Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03061565 |
|
Recruitment Status :
Recruiting
First Posted : February 23, 2017
Last Update Posted : August 22, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Traumatic brain injury is catastrophic event that commonly require treatment in an intensive care unit. Management is mainly supportive aiming at avoiding hypoxia, hypotension, hypoglycaemia and increased intracerebral pressure. Thus far efforts to find a specific pharmacologic therapies have been disappointing. Recently it was demonstrated that recombinant erythropoietin has been found to decrease mortality at six months from injury but without significantly improving functional neurological outcome (GOSe). Whether this survival benefit of EPO is sustained beyond 6 months is unknown.
In the current study survival data will be collected centrally and patients alive or person responsible will be invited to participate in an evaluation of neurological function and quality of life. Factors associated with time to death as well as factors associated with long term quality of life will be determined with statistical methods.
| Condition or disease | Intervention/treatment |
|---|---|
| Traumatic Brain Injury | Drug: erythropoietin Drug: Placebos |
Aim: In this post hoc study of a RCT the primary aim is to determine the effect of EPO compared to placebo in improving outcome, including survival, neurological function and quality of life two years after the conclusion of the EPO-TBI study (two to seven years after moderate or severe TBI occurring in individual patients).
Design: A long term follow-up study of a prospective, multi-centre, double blind, phase III, randomised controlled trial.
Methods: Survival status at the time when this follow-up trial is executed will obtained in all patients. Time from injury will vary between 2 to 7 years depending on when the patient was enrolled. This information will obtained from hospital notes, national register offices and/or national statistical bureaus. Since the trial was an international RCT, strategies may vary and will take into account local circumstances. Local plans will be developed by the local principal investigators and approved by the management committee.
Data includes
- Survival status at long term follow up (alive/dead)
- Time from injury to assessment (days)
- If the patients is deceased, time of death and time from injury in days
Quality of life assessment
Patients (or a proxy - generally a close family member) who are alive at 2-7 years after randomisation will be interviewed by trained assessors. The same contact person as used in the primary trial will be contacted primarily. Consent will be obtained for the conduction for long term assessment. Assessors will use a standardized structured telephone questionnaires to determine GOSE and QOL. Neurological outcomes will then be defined as favourable (GOSE 5 to 8; moderate disability and good recovery) or unfavourable (GOSE 1 to 4; death and severe disability). Data include:
- Time of assessment
- Time from injury in days
- Follow-up GOSE
- Follow-up EQ-5D
- Follow-up SF-12
| Study Type : | Observational |
| Estimated Enrollment : | 603 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Prospective |
| Official Title: | Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury A Follow-up Study of an International Randomised Controlled Trial |
| Actual Study Start Date : | August 1, 2017 |
| Estimated Primary Completion Date : | May 31, 2019 |
| Estimated Study Completion Date : | May 31, 2019 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Erythropoietin
Patients were treated with EPO during the EPO-TBI study in 2010-2014.
|
Drug: erythropoietin
Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
Other Name: EPOETIN ALFA |
|
Placebo
Patients were treated with placebo during the EPO-TBI study in 2010-2014.
|
Drug: Placebos
Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
Other Name: Sodium chloride |
- Mortality and time to mortality at least 2 years from injury [ Time Frame: 2-7 years from injury ]Survival status with time to death in those deceased
- Glasgow outcome scale extended [ Time Frame: 2-7 years from injury ]Neurological outcome
- SF-12 [ Time Frame: 2-7 years from injury ]Quality of life scale
- EQ-5D [ Time Frame: 2-7 years from injury ]Quality of life scale
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 15 Years to 75 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Participation in the EPO-TBI study without withdrawal of informed consent.
Exclusion criteria:
- Failure to to consent for the conduction of the follow-up assessment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03061565
| Contact: Markus B Skrifvars | +61399030343 | markus.skrifvars@monash.edu | |
| Contact: Lorraine Little | +61399030513 | lorraine.little@monash.edu |
| Australia, Victoria | |
| Australian and New Zealand Intensive Care Research Centre, Monash University | Recruiting |
| Melbourne, Victoria, Australia, 3004 | |
| Contact: Lorraine Little +61 3 9903 0513 lorraine.little@monash.edu | |
| Principal Investigator: | Rinaldo Bellomo | ANZIC-RC Monash University |
| Responsible Party: | David James Cooper, Director, Australian and New Zealand Intensive Care Research Centre |
| ClinicalTrials.gov Identifier: | NCT03061565 History of Changes |
| Other Study ID Numbers: |
ANZIC-RC EPO-TBI Long term |
| First Posted: | February 23, 2017 Key Record Dates |
| Last Update Posted: | August 22, 2018 |
| Last Verified: | August 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Keywords provided by David James Cooper, Australian and New Zealand Intensive Care Research Centre:
|
erythropoietin traumatic brain injury |
Additional relevant MeSH terms:
|
Wounds and Injuries Brain Injuries Brain Injuries, Traumatic Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System Epoetin Alfa Hematinics |